Physician profile
Tulio E Rodriguez
NPI 1831176007
$337,229.32
in general payments reported to CMS, 2019-2025
37 companies · $46K in 2025
The $46K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $26K · 2021: $40K · 2022: $107K · 2023: $35K · 2024: $37K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Consulting Fee: $13K · Travel and Lodging: $11K · Food and Beverage: $5,697 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,120.50 |
| Consulting Fee | $13,010.00 |
| Travel and Lodging | $10,658.48 |
| Food and Beverage | $5,697.47 |
| Education | $138.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $161,865.30 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $67,597.42 | 2019-2023 | Vyxeos |
| Kite Pharma, INC. | $64,845.06 | 2019-2025 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $16,144.97 | 2019-2025 | Ninlaro, Fruzaqla, Livtencity |
| E.R. Squibb & Sons, L.L.C. | $8,313.74 | 2019 | |
| Gilead Sciences, INC. | $4,727.69 | 2019-2021 | |
| Incyte Corporation | $4,364.75 | 2019-2024 | Jakafi |
| Ipsen Biopharmaceuticals, INC | $2,200.85 | 2024 | Tazverik |
| Celgene Corporation | $1,781.94 | 2019-2025 | Reblozyl, Pomalyst, Onureg |
| Glaxosmithkline, LLC. | $1,229.03 | 2024-2025 | Ojjaara |
| Janssen Biotech, INC. | $755.55 | 2023-2025 | Carvykti, Rybrevant, Darzalex |
| Stemline Therapeutics INC. | $573.79 | 2021-2024 | Elzonris |
| Astellas Pharma US INC | $515.95 | 2019-2025 | Cresemba, Xospata |
| Astrazeneca Pharmaceuticals Lp | $376.84 | 2023-2025 | Calquence |
| Pfizer INC. | $307.19 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.29 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $202.95 | 2023-2025 | |
| Beigene USA, INC. | $163.93 | 2023-2024 | Brukinsa |
| Genmab U.S., INC. | $149.51 | 2023-2025 | Epkinly |
| Sanofi-Aventis U.S. LLC | $133.38 | 2023 | |
| Pharmaessentia USA Corporation | $122.46 | 2024-2025 | Besremi |
| Genentech USA, INC. | $106.39 | 2024-2025 | Polivy, Columvi, Lunsumio |
| Merck Sharp & Dohme LLC | $56.31 | 2024-2025 | Prevymis, Zerbaxa |
| Karyopharm Therapeutics INC. | $54.38 | 2025 | Xpovio |
| Servier Pharmaceuticals LLC | $52.59 | 2023-2025 | |
| Syndax Pharmaceuticals, INC. | $52.37 | 2025 | |
| Beone Medicines USA, INC. | $48.55 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $31.88 | 2023 | Epkinly, Imbruvica |
| Kyowa Kirin, INC. | $29.92 | 2025 | |
| Amgen INC. | $28.57 | 2019 | |
| Invivyd INC | $23.67 | 2025 | Pemgarda |
| Daiichi Sankyo INC. | $23.41 | 2024 | Enhertu |
| Lilly USA, LLC | $22.58 | 2021 | |
| Rigel Pharmaceuticals, INC. | $21.28 | 2023 | Tavalisse, Rezlidhia |
| Geron Corporation | $19.83 | 2025 | Rytelo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tulio Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.